Related articles:

SCYNEXIS Inc.: SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences
January 31, 2017

SCYNEXIS Inc.: SCYNEXIS, Inc. Reports Second Quarter 2016 Financial Results and Provides Company Update
August 08, 2016

SCYNEXIS Inc.: SCYNEXIS, Inc. Announces Sale of Cyclophilin Inhibitor Assets to Cypralis Limited
July 13, 2016

SCYNEXIS Inc.: SCYNEXIS, Inc. Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors
June 08, 2016

SCYNEXIS Inc.: SCYNEXIS, Inc. Reports First Quarter 2016 Financial Results and Provides Company Update
May 09, 2016

SCYNEXIS Inc.: SCYNEXIS, Inc. Reports Third Quarter 2015 Financial Results and Provides Company Update
November 13, 2015

SCYNEXIS Inc.: SCYNEXIS Appoints Rajeshwar Motheram as Vice President, Pharmaceutical Development
October 07, 2015

SCYNEXIS Inc.: SCYNEXIS, Inc. Announces Board of Directors Transitions
September 28, 2015

SCYNEXIS Inc.: SCYNEXIS, Inc. Reports Second Quarter 2015 Financial Results
August 19, 2015

SCYNEXIS Inc.: SCYNEXIS, Inc. Announces Changes to Board of Directors
June 10, 2015

SCYNEXIS Inc.: SCYNEXIS, Inc. Reports First Quarter 2015 Financial Results
May 15, 2015

SCYNEXIS Inc.: SCYNEXIS, Inc. Reports Full Year 2014 Financial Results
March 30, 2015

SCYNEXIS Inc.: SCYNEXIS, Inc. Appoints Steven C. Gilman, Ph.D., to Board of Directors
February 27, 2015

SCYNEXIS Inc.: SCYNEXIS, Inc. Announces Appointment of Two Seasoned Industry Professionals to Its Board of Directors
December 03, 2014

SCYNEXIS Inc.: SCYNEXIS, Inc. Reports Third Quarter 2014 Financial Results
November 13, 2014

SCYNEXIS Inc.: SCYNEXIS, Inc. Enters Into Worldwide Agreement With Waterstone Pharmaceutical for the Development and Commercialization of SCY-635 for Viral Diseases
November 03, 2014

SCYNEXIS Inc.: SCYNEXIS, Inc. Reports Second Quarter 2014 Financial Results
August 13, 2014

SCYNEXIS Inc.: SCYNEXIS Announces Launch of Initial Public Offering of Common Stock
March 24, 2014